Large-Scale Prediction of Beneficial Drug Combinations Using Drug Efficacy and Target Profiles

The identification of beneficial drug combinations is a challenging issue in pharmaceutical and clinical research toward combinatorial drug therapy. In the present study, we developed a novel computational method for large-scale prediction of beneficial drug combinations using drug efficacy and target profiles. We designed an informative descriptor for each drug-drug pair based on multiple drug profiles representing drug-targeted proteins and Anatomical Therapeutic Chemical Classification System codes. Then, we constructed a predictive model by learning a sparsity-induced classifier based on known drug combinations from the Orange Book and KEGG DRUG databases. Our results show that the proposed method outperforms the previous methods in terms of the accuracy of high-confidence predictions, and the extracted features are biologically meaningful. Finally, we performed a comprehensive prediction of novel drug combinations for 2,639 approved drugs, which predicted 142,988 new potentially beneficial drug-drug pairs. We showed several examples of successfully predicted drug combinations for a variety of diseases.

[1]  Kyoung Mii Park,et al.  CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules , 2012, PloS one.

[2]  Chih-Jen Lin,et al.  LIBLINEAR: A Library for Large Linear Classification , 2008, J. Mach. Learn. Res..

[3]  W. Bonadio,et al.  Safe and effective method for application of tetracaine, adrenaline, and cocaine to oral lacerations. , 1996, Annals of emergency medicine.

[4]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[5]  R Michael Siatkowski,et al.  Ocular rosacea in childhood. , 2004, American journal of ophthalmology.

[6]  E. Marcotte,et al.  A flaw in the typical evaluation scheme for pair-input computational predictions , 2012, Nature Methods.

[7]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[8]  D Hare,et al.  The Orange Book: the Food and Drug Administration's advice on therapeutic equivalence. , 1990, American pharmacy.

[9]  Yang Zhang,et al.  Combination of erythromycin and dexamethasone improves corticosteroid sensitivity induced by CSE through inhibiting PI3K-δ/Akt pathway and increasing GR expression. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[10]  Yasuo Tabei,et al.  Identification of chemogenomic features from drug–target interaction networks using interpretable classifiers , 2012, Bioinform..

[11]  Lei Huang,et al.  DrugComboRanker: drug combination discovery based on target network analysis , 2014, Bioinform..

[12]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[13]  Mark Goadrich,et al.  The relationship between Precision-Recall and ROC curves , 2006, ICML.

[14]  R. Sharan,et al.  INDI: a computational framework for inferring drug interactions and their associated recommendations , 2012, Molecular systems biology.

[15]  Ravi Iyengar,et al.  Systems Pharmacology of Adverse Event Mitigation by Drug Combinations , 2013, Science Translational Medicine.

[16]  Yasuo Tabei,et al.  Inferring protein domains associated with drug side effects based on drug-target interaction network , 2013, BMC Systems Biology.

[17]  Michael Shannon,et al.  Drug Interactions—A Review , 2005 .

[18]  Xing-Ming Zhao,et al.  Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..

[19]  Susumu Goto,et al.  Network-Based Analysis and Characterization of Adverse Drug-Drug Interactions , 2011, J. Chem. Inf. Model..

[20]  S. Vilar,et al.  Detection of Drug-Drug Interactions by Modeling Interaction Profile Fingerprints , 2013, PloS one.

[21]  M. Relling,et al.  Moving towards individualized medicine with pharmacogenomics , 2004, Nature.

[22]  W. E. Woods,et al.  Regulatory significance of procaine residues in plasma and urine samples: preliminary communication. , 1996, Equine veterinary journal.

[23]  Mark J Mannis,et al.  Efficacy and Safety of Recurrent Pterygium Surgery Using Human Processed Pericardium , 2002, Cornea.

[24]  Yoshihiro Yamanishi,et al.  Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008, ISMB.

[25]  Julian Blagg,et al.  Structure–Activity Relationships for In vitro and In vivo Toxicity , 2006 .

[26]  B. Roth,et al.  The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? , 2000 .

[27]  D. Bojanic,et al.  Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. , 2005, Drug discovery today.

[28]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[29]  Li Mao,et al.  Algorithmic Guided Screening of Drug Combinations of Arbitrary Size for Activity against Cancer Cells , 2022 .

[30]  Carol Friedman,et al.  Drug-drug interaction through molecular structure similarity analysis , 2012, J. Am. Medical Informatics Assoc..

[31]  J. Irwin,et al.  Docking and chemoinformatic screens for new ligands and targets. , 2009, Current opinion in biotechnology.

[32]  Yoshihiro Yamanishi,et al.  KEGG for linking genomes to life and the environment , 2007, Nucleic Acids Res..

[33]  A S Hossain,et al.  Comparison of salbutamol and ipratropium bromide versus salbutamol alone in the treatment of acute severe asthma. , 2013, Mymensingh medical journal : MMJ.

[34]  Gilles Marcou,et al.  Computational chemogenomics: Is it more than inductive transfer? , 2014, Journal of Computer-Aided Molecular Design.

[35]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[36]  Ruth Nussinov,et al.  Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.

[37]  Xia Li,et al.  The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: A meta-analysis of randomized controlled trials , 2013, Journal of the Neurological Sciences.

[38]  S. Ray,et al.  Bicarbonate Plus Epinephrine Shortens the Onset and Prolongs the Duration of Sciatic Block Using Chloroprocaine Followed by Bupivacaine in Sprague-Dawley Rats , 2008, Regional Anesthesia & Pain Medicine.

[39]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[40]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[41]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[42]  U. R. Chowdhury,et al.  Dopamine Increases the Efficacy of Anticancer Drugs in Breast and Colon Cancer Preclinical Models , 2008, Clinical Cancer Research.

[43]  Damian Szklarczyk,et al.  STITCH 4: integration of protein–chemical interactions with user data , 2013, Nucleic Acids Res..

[44]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[45]  Jürgen Bajorath,et al.  Classification of Compounds with Distinct or Overlapping Multi-Target Activities and Diverse Molecular Mechanisms Using Emerging Chemical Patterns , 2013, J. Chem. Inf. Model..

[46]  George Hripcsak,et al.  Similarity-based modeling in large-scale prediction of drug-drug interactions , 2014, Nature Protocols.

[47]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[48]  Igor I. Baskin,et al.  Predicting Ligand Binding Modes from Neural Networks Trained on Protein-Ligand Interaction Fingerprints , 2013, J. Chem. Inf. Model..

[49]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..